Lysosomal Storage Diseases: Clinical Trials

188 trials for Lysosomal Storage Diseases, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

107 completed, 23 terminated, 21 active not recruiting, 15 recruiting. 188 Phase 1, 115 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 1188Completed 107, Terminated 23, Active not recruiting 21, Recruiting 15, Withdrawn 7, Not yet recruiting 6, Unknown 4, Suspended 3, Enrolling by invitation 2
Phase 2115Completed 57, Active not recruiting 18, Terminated 15, Recruiting 10, Not yet recruiting 4, Withdrawn 4, Suspended 3, Unknown 3, Enrolling by invitation 1

Follow Lysosomal Storage Diseases: new trials by email Literature Review of Lysosomal Storage Diseases trials Research Report on Lysosomal Storage Diseases

Trials (filtered) newest first · largest first

All 188 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Single Injection of rAAV9-CMV-hNAGLUop Gene for Patients With Mucopolysaccharidosis (MPS) IIIB
rAAV9-CMV-hNAGLUop - Sanfilippo Syndrome (MPS III)
Phase 1 / Phase 2Not yet recruitingNeuroGT92027-01-182026-09-14
Prenatal Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis Clinical Trial
Gene Transfer with an AAV9 Vector Expressing Human ß-galactosidase - GM1 Gangliosidoses, GM1 Gangliosidosis, Type I
Phase 1Not yet recruitingTippi Mackenzie52027-01-012026-08-31
4SCAR-T Therapy Targeting GD2, PSMA and CD276 for Treating Neuroblastoma
GD2, PSMA and CD276 CAR-T cells - Neuroblastoma
Phase 1 / Phase 2Not yet recruitingShenzhen Geno-Immune Medical Institute1002026-12-312026-10-30
A Study of S-606001 as Monotherapy in Participants With Late-onset Pompe Disease (LOPD)
S-606001 - Pompe Disease
Phase 1Not yet recruitingShionogi152026-11-302026-11-17
Safety and Efficacy of scAAV9/AGA Gene Therapy in Participants With Aspartylglucosaminuria (AGU)
scAAV9/AGA - Aspartylglucosaminuria, Aspartylglucosamidase (AGA) Deficiency
Phase 1 / Phase 2Enrolling by invitationRare Trait Hope92026-11-012026-10-27
A Phase I/II Clinical Study to Evaluate the Safety and Efficacy of VGN-R08b in Patients With Type III Gaucher's Disease
VGN-R08b - Gaucher Disease Type 3
Phase 1 / Phase 2Not yet recruitingShanghai Vitalgen BioPharma Co., Ltd.122026-05-142026-05-22
A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of DNL952 in Adult Participants With Late-Onset Pompe Disease
DNL952 - Late-onset Pompe Disease
Phase 1 / Phase 2RecruitingDenali Therapeutics Inc.322026-05-122026-11-18
A Study to Evaluate Safety, Tolerability, and Efficacy of AB-1009 Gene Therapy (GAA Gene) in Adult Participants With Late-Onset Pompe Disease (PROGRESS-GT LOPD)
AB-1009 (GAA Gene) - Pompe Disease (Late-onset), Pompe Disease Late-Onset
Phase 1 / Phase 2RecruitingAskBio Inc122026-04-152026-10-13
Safety and Efficacy of AAV9. hMCOLN1co For Patients With Mucolipidosis Type IV
AAV9.hMCOLN1co - Mucolipidosis Type IV
Phase 1Enrolling by invitationThe Children's Hospital of Zhejiang University School of Medicine12026-01-132026-02-10
DFT383 in Pediatric Participants With Nephropathic Cystinosis
DFT383 - Nephropathic Cystinosis
Phase 1 / Phase 2RecruitingNovartis Pharmaceuticals302025-06-022026-10-16
The Safety and Efficacy of Intravenous EXG110 in Patients With Fabry Disease
EXG110 Injection - Fabry Disease
Phase 1 / Phase 2Not yet recruitingGuangzhou Jiayin Biotech Ltd162025-03-012025-02-11
Phase 1 Study of GC1130A in Patients With Sanfilippo Syndrome Type A (MPS IIIA)
GC1130A - Sanfilippo Syndrome Type A
Phase 1Active not recruitingGC Biopharma Corp92024-11-212026-09-08
An Open-label Phase I/II Study of JR-446 in Mucopolysaccharidosis Type IIIB
JR-446 - Mucopolysaccharidosis III-B
Phase 1 / Phase 2Active not recruitingJCR Pharmaceuticals Co., Ltd.102024-11-052026-10-01
A First-in-Human, Single- and Multiple-Ascending Dose Study of YH35995 in Healthy Adult Male Participants
YH35995, Placebo - Healthy Participants
Phase 1Active not recruitingYuhan Corporation942024-07-292026-07-28
A Clinical Study Evaluating the Safety, Tolerability, and Initial Efficacy of JWK008 in Patients With Mucopolysaccharidosis Type I
JWK008 Single intravenous infusion administration - Mucopolysaccharidosis Type I
Phase 1RecruitingWest China Hospital62024-07-222024-07-25
A Clinical Study Evaluating LY-M001 Injection in the Treatment of Adult Patients With Type I Gaucher Disease
LY-M001 - Gaucher Disease Type 1
Phase 1 / Phase 2RecruitingLingyi Biotech Co., Ltd.122024-07-052026-01-26
Safety, PK/PD, and Exploratory Efficacy Study of AMT-191 in Classic Fabry Disease
AMT-191 - Fabry Disease
Phase 1 / Phase 2RecruitingUniQure Biopharma B.V.202024-06-052026-09-24
Long Term Follow-up Study of Type-1 Gaucher Subjects Post FLT201 Dose (GALILEO-2)
FLT201 - Gaucher Disease, Type 1
Phase 1 / Phase 2Active not recruitingSpur Therapeutics752024-05-132025-11-04
Evaluation of the Safety and Efficacy of Late-onset Pompe Disease Gene Therapy Drug
GC301 - Pompe Disease (Late-onset)
Phase 1 / Phase 2RecruitingGeneCradle Inc332024-04-192026-11-13
Study of DNL126 in Pediatric Participants With Mucopolysaccharidosis Type IIIA (Sanfilippo Syndrome Type A)
DNL126, Prophylactic immunomodulatory therapy - Mucopolysaccharidosis Type IIIA
Phase 1 / Phase 2RecruitingDenali Therapeutics Inc.302023-12-072026-11-02

Showing 20 of 188. Sign in to see all of them.

Narrower conditions

Gaucher Disease (32)  ·  Mucopolysaccharidosis I (28)  ·  Fabry Disease (23)  ·  Glycogen Storage Disease Type II (20)  ·  Mucopolysaccharidosis II (20)  ·  Mucopolysaccharidosis III (20)  ·  Mucopolysaccharidoses (12)  ·  Genetic Diseases, Inborn (11)  ·  Leukodystrophy, Metachromatic (11)  ·  Metabolic Diseases (11)  ·  Metabolism, Inborn Errors (10)  ·  Sudden Infant Death (10)  ·  Mucopolysaccharidosis IV (8)  ·  Niemann-Pick Disease, Type C (8)

Broader conditions

Nutritional and Metabolic Diseases (188)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (187)  ·  Metabolism, Inborn Errors (178)  ·  Genetic Diseases, Inborn (177)  ·  Metabolic Diseases (177)  ·  Nervous System Diseases (133)  ·  Brain Diseases (111)  ·  Central Nervous System Diseases (111)  ·  Brain Diseases, Metabolic (110)  ·  Brain Diseases, Metabolic, Inborn (110)  ·  Lysosomal Storage Diseases, Nervous System (110)  ·  Carbohydrate Metabolism, Inborn Errors (94)  ·  Lipid Metabolism, Inborn Errors (91)  ·  Lipid Metabolism Disorders (89)

Interventions

Iduronidase (6)  ·  eliglustat (6)  ·  migalastat (5)  ·  2-Hydroxypropyl-beta-cyclodextrin (4)  ·  Sirolimus (4)  ·  larazotide acetate (4)  ·  valanafusp alpha (4)  ·  Cysteamine (3)  ·  GAA protein, human (3)  ·  GALNS protein, human (3)  ·  Methylprednisolone (3)  ·  Rituximab (3)  ·  fludarabine (3)  ·  miglustat (3)  ·  Acetylcysteine (2)

Sponsors

Shire (9)  ·  Genzyme, a Sanofi Company (8)  ·  Amicus Therapeutics (7)  ·  ArmaGen, Inc (5)  ·  JCR Pharmaceuticals Co., Ltd. (5)  ·  BioMarin Pharmaceutical (4)  ·  Duke University (4)  ·  Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (4)  ·  Protalix (4)  ·  Sanofi (4)  ·  Spur Therapeutics (4)  ·  University of Florida (4)  ·  Alexion Pharmaceuticals, Inc. (3)  ·  Cyclo Therapeutics, Inc. (3)  ·  Denali Therapeutics Inc. (3)

Countries

United States (115)  ·  United Kingdom (39)  ·  Germany (20)  ·  Canada (17)  ·  France (17)  ·  Brazil (15)  ·  Australia (13)  ·  Netherlands (10)  ·  Spain (10)  ·  China (8)  ·  Israel (7)  ·  Italy (7)  ·  Japan (7)  ·  Denmark (6)  ·  South Korea (5)

Top investigators

Joanne Kurtzberg, MD (4)  ·  Forbes D Porter, M.D. (3)  ·  Patrice Rioux, MD PhD (3)  ·  Alan H Cohen, MD (2)  ·  Caroline Hastings, MD (2)  ·  Celeste Decker, MD (2)  ·  Dugald Seely, ND (2)  ·  Dwight D Koeberl, MD, PhD (2)  ·  May Orfali, MD (2)  ·  Patrice P Rioux, MD PhD (2)

Results publications

PMID 37624739, PMID 22547151, PMID 25421091, PMID 29526614, PMID 29976218, PMID 33332761, PMID 35835061, PMID 36196048, PMID 36279795, PMID 36299240, PMID 11231629, PMID 11399225, PMID 15324318, PMID 19277123, PMID 19775921, PMID 19892975, PMID 19948615, PMID 20299511, PMID 21637107, PMID 22794786, PMID 23348766, PMID 23494656, PMID 23497636, PMID 23510062, PMID 23570273, PMID 23845948, PMID 23860343, PMID 23966770, PMID 24296492, PMID 24443373, PMID 25758611, PMID 26000324, PMID 26048034, PMID 27136905, PMID 27211612, PMID 27289174, PMID 27536442, PMID 28088251, PMID 28119821, PMID 28374935, PMID 28657663, PMID 28969890, PMID 30025991, PMID 30177353, PMID 30337566, PMID 30467742, PMID 30595526, PMID 30834538, PMID 31187454, PMID 31575939

NIH funding

2019 (3), 2009 (1), 2015 (1), 2017 (1), 2018 (1), 2023 (1), 2025 (1), K12CA120780 (1), P01HL059412 (1), U01HD090845 (1), U54NS065768 (1)